Clinical trial
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in…
NCT00326144 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00326144 |
|---|---|
| Title | Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder |
| Acronym | OPAL |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate |
| Enrollment | 310 |
| Start date | Apr 1, 2006 |
| Completion | May 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: